China Health Industries Holdings, Inc. Completed the Strategic Transformation from Traditional Health Supplement Products Manufacturer to Hemp Derivative Products Pioneer
Harbin, China--(Newsfile Corp. - December 20, 2018) - China Health Industries Holdings, Inc. (OTCQB: CHHE) ("China Health Industries", the "Company" or "Us") has completed the strategic transformation from being a traditional health supplement products manufacturer to a hemp derivative products pioneer. The Company's hemp derivative products have been launched into the Chinese market since May 2018, including Hemp Oil, Hemp Protein Powder, Hemp Polypeptide and Hemp Cosmetics.
For the three months ended September 30, 2018, the sales revenue of our hemp derivative products was $1,620,912, accounting for 75.68% of the Company's total revenue. The hemp derivative products are expected to become the driving force to increase profit in the fiscal year of 2019, as it is estimated that the sales revenue of the four hemp derivative products is to reach around $6.5 million in the fiscal year of 2019.
The CEO of China Health Industries, Mr. Xin Sun, said: "The four hemp derivative products including Hemp Oil, Hemp Protein Powder, Hemp Polypeptide and Hemp Cosmetics, which have been available in the market since May 2018, are highly appraised by our customers. The flowers, leaves, stems and roots of the hemp can be utilized to produce various hemp products. In the upcoming years, we will invest more resources on expanding our offering of hemp products in the market and developing new hemp products to meet customers' needs."
China Health Industries Holdings, Inc. (www.chinahealthindustries.com) is a holding company vertically integrated with the operations in its subsidiaries in China, specializing in R&D, and production, marketing and distribution of hemp derivative products, medicines and health supplement products.
China Health owns GMP certified plants and facilities, and manufactures 21 CFDA approved medicines and 14 health supplement products covering 5 kinds of dosage forms, including soft capsule, hard capsule, tablet, granule and oral liquid. Our product series covers hemp derivative foods, hemp derivative medicines, externally used medicines and health foods.
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
China Health Industries Holdings, Inc.